Skip to main content

Advertisement

Table 2 Tumour response in all patients

From: Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

  Patients, n(%)
Response according to irRC Total (N = 833) BRAF-mutation positive (n = 169) BRAF wildtype (n = 291) NRAS-mutation positive (n = 14) NRAS wildtype (n = 67) Any irAE (n = 278) No irAE (n = 555)
irCR 29 (3) 9 (6) 12 (4) 2 (14) 4 (6) 10 (4) 19 (3)
irPR 82 (10) 19 (11) 27 (9) 2 (14) 9 (13) 31 (11) 51 (9)
irSD 175 (21) 36 (21) 76 (26) 4 (29) 20 (30) 57 (21) 118 (21)
irPD 547 (66) 105 (62) 176 (61) 6 (43) 34 (51) 180 (65) 367 (66)
irDCR 286 (34) 64 (38) 115 (39) 8 (57) 33 (49) 98 (35) 188 (34)
  1. irRC: immune-related response criteria; irAE: immune-related adverse event; irCR: immune-related complete response; irPR: immune-related partial response; irSD: immune-related stable disease; irPD: immune-related progressive disease; irDCR: immune-related disease control rate.